SCHEMBL29035289

SCHEMBL29035289

CC(C)(C)OC(=O)N1CC(c2ccc(F)cc2)=C[C@H]1CO

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC2 Q92769 3/20 0.39
HDAC8 Q9BY41 1/20 0.38
MMP13 P45452 1/20 0.37
GRM5 P41594 1/20 0.36
GRM1 Q13255 1/20 0.36
UCHL1 P09936 1/20 0.36
RORC P51449 2/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
PTPN2 P17706 1/20 0.34
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34
NR1H2 P55055 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29035291 1.00 TACR1 (0.41) TACR1MEN1KMT2AHDAC1HDAC2
SCHEMBL23632067 0.88 NR1H2 (0.42) TACR1MEN1KMT2AMMP13UCHL1
SCHEMBL23631967 0.88 NR1H2 (0.42) TACR1MEN1KMT2AMMP13UCHL1
SCHEMBL29035461 0.88 UCHL1 (0.46) TACR1MEN1KMT2AUCHL1NR1H2
SCHEMBL29035464 0.88 UCHL1 (0.46) TACR1MEN1KMT2AUCHL1NR1H2
SCHEMBL25363051 0.80 HTT (0.35) MEN1KMT2A
SCHEMBL25363056 0.80 HTT (0.35) MEN1KMT2A
SCHEMBL30577885 0.80 MEN1 (0.41) TACR1MEN1KMT2AUCHL1NR1H2
SCHEMBL29035415 0.80 MEN1 (0.36) MEN1KMT2AHDAC1HDAC2HDAC8
SCHEMBL29035412 0.80 MEN1 (0.36) MEN1KMT2AHDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed